Drug Search Results
More Filters [+]

BAY86-6150

Alternative Names: bay86-6150, bay866150, bay86 6150, b-0189, b0189
Latest Update: 2015-07-01
Latest Update Note: Clinical Trial Update

Product Description

a modified recombinant activated factor VII (FVIIa). In the single patient with haemophilia A who developed anti-BAY 86-6150 antibodies, results of T-cell epitope mapping indicated BAY 86-6150 was no more immunogenic than WT-FVIIa. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/27501279/)

Mechanisms of Action: Eptacog Alfa Cleaver

Novel Mechanism: Yes

Modality: Coagulation Factor

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BAY86-6150

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Hemophilia A|Hemophilia B

Phase 1: Hemophilia B|Hemophilia A

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

U1111-1133-2156

P3

Completed

Hemophilia B|Hemophilia A

2014-03-01

MATCHBOX

P1

Completed

Hemophilia B|Hemophilia A

2009-12-01

Recent News Events

Date

Type

Title